Your browser doesn't support javascript.
loading
Treatment of patients with Graves' ophthalmopathy by immunosuppressive agent and 99Tc-MDP / 生物医学工程学杂志
Article de Zh | WPRIM | ID: wpr-263604
Bibliothèque responsable: WPRO
ABSTRACT
The purpose of this study was to evaluate the efficacy of immunosuppressive agents, 99Tc-MDP and both of them in treating patients with Graves' ophthalmopathy(GO). The efficacy was evaluated by randomized controlled trial involving a total of 66 patients. In 22 patients treated with immunosuppressive agents, the general efficacy rate was 19/22, the incidence rate of serious side-effect was 8/22. In 20 patients treated with 99Tc-MDP, the general efficacy rate was 17/20, the incidence rate of serious side-effect was 2/20. In 24 patients treated with immunosuppressive agents and 99Tc-MDP, the general efficacy rate was 22/24, the incidence rate of serious side-effect was 2/24. The results suggested that in the treatment of Graves' ophthalmopathy, when satisfactory efficacy was obtained, the serious side-effect and 'rebound' of symptom could be avoided by using immunosuppressive agents in combination with 99Tc-MDP.
Sujet(s)
Texte intégral: 1 Indice: WPRIM Sujet Principal: Médronate de technétium (99mTc) / Utilisations thérapeutiques / Traitement médicamenteux / Ophtalmopathie basedowienne / Immunosuppresseurs Type d'étude: Clinical_trials Limites du sujet: Humans langue: Zh Texte intégral: Journal of Biomedical Engineering Année: 2002 Type: Article
Texte intégral: 1 Indice: WPRIM Sujet Principal: Médronate de technétium (99mTc) / Utilisations thérapeutiques / Traitement médicamenteux / Ophtalmopathie basedowienne / Immunosuppresseurs Type d'étude: Clinical_trials Limites du sujet: Humans langue: Zh Texte intégral: Journal of Biomedical Engineering Année: 2002 Type: Article